| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 408 | 444 | 398 | 435 | 459 | 475 | 445 | 447 | 545 | 452 | 604 | 554 | 619 | 613 | 605 | 627 | 786 | 811 | 796 | 767 | 902 | 889 | 852 | 878 | 1,010 | 1,011 | 972 | 964 |
| Expenses | 326 | 354 | 304 | 353 | 350 | 356 | 339 | 362 | 367 | 334 | 377 | 405 | 442 | 466 | 473 | 500 | 612 | 625 | 618 | 599 | 664 | 638 | 621 | 664 | 724 | 730 | 709 | 723 |
| EBITDA | 82 | 90 | 94 | 81 | 109 | 119 | 106 | 85 | 178 | 119 | 227 | 149 | 177 | 146 | 133 | 127 | 174 | 186 | 178 | 168 | 238 | 251 | 231 | 215 | 286 | 281 | 263 | 241 |
| Operating Profit % | 20 % | 19 % | 20 % | 16 % | 22 % | 22 % | 21 % | 18 % | 30 % | 25 % | 31 % | 23 % | 27 % | 21 % | 21 % | 20 % | 22 % | 23 % | 22 % | 21 % | 26 % | 28 % | 26 % | 23 % | 28 % | 27 % | 26 % | 24 % |
| Depreciation | 15 | 15 | 15 | 12 | 16 | 16 | 17 | 17 | 17 | 18 | 17 | 17 | 18 | 16 | 17 | 22 | 26 | 28 | 28 | 32 | 31 | 32 | 34 | 41 | 41 | 42 | 42 | 46 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 8 | 8 | 14 | 12 | 10 | 13 | 9 | 6 | 2 | 3 | 2 |
| Profit Before Tax | 66 | 75 | 78 | 68 | 92 | 102 | 88 | 67 | 157 | 99 | 209 | 132 | 158 | 129 | 114 | 103 | 142 | 150 | 141 | 123 | 194 | 209 | 184 | 165 | 240 | 237 | 218 | 193 |
| Tax | 21 | 23 | 28 | 22 | 30 | 8 | 22 | 17 | 38 | 25 | 54 | 31 | 39 | 32 | 30 | 18 | 37 | 39 | 35 | 35 | 52 | 58 | 50 | 38 | 63 | 62 | 56 | 47 |
| Net Profit | 46 | 52 | 50 | 47 | 62 | 94 | 66 | 50 | 120 | 74 | 154 | 101 | 119 | 98 | 84 | 85 | 105 | 111 | 106 | 88 | 142 | 151 | 134 | 126 | 177 | 175 | 163 | 146 |
| EPS in ₹ | 5.46 | 6.14 | 6.07 | 5.68 | 7.73 | 11.67 | 8.26 | 6.30 | 15.45 | 9.55 | 19.94 | 13.02 | 15.38 | 12.65 | 10.85 | 10.98 | 13.59 | 14.37 | 13.72 | 11.33 | 9.20 | 9.72 | 8.62 | 8.22 | 11.39 | 11.24 | 10.46 | 9.36 |
J B Chemicals and Pharmaceuticals
1,676.30
-14.10
(-0.83%)
Market Cap
26,315.70 Cr
EPS
35.66
PE Ratio
39.94
Dividend Yield
0.50 %
Industry
Healthcare52 Week High
2,030.00
52 Week Low
1,385.75
PB Ratio
7.67
Debt to Equity
0.18
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from12 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,677.60 | #1 4,07,839.00 | 35.55 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 42.28 | |
6,612.00 | 1,76,045.50 | 80.38 | 8,184.00 | 0.89 | 1,600 | 23.05 | 63.47 | |
1,465.70 | 1,19,276.70 | 22.62 | 26,520.70 | 14.17 | 4,155 | 30.28 | 44.20 | |
3,174.70 | 1,06,986.00 | 55.56 | 10,785.70 | 11.59 | 1,656 | 10.91 | 44.55 | |
1,251.20 | 1,04,156.70 | #1 18.42 | 28,905.40 | 12.36 | 5,578 | 21.14 | 67.52 | |
2,467.70 | 1,01,568.60 | 51.21 | 10,615.60 | 19.57 | 1,942 | -10.91 | 48.86 | |
930.00 | 93,051.50 | 19.92 | 19,831.50 | 13.82 | 3,831 | -0.19 | 63.14 | |
1,957.70 | 89,943.10 | 27.40 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 43.05 | |
1,147.80 | 68,122.20 | 19.71 | 29,559.20 | 17.55 | 3,169 | -0.50 | 43.00 | |
30,455.00 | 64,491.60 | 45.58 | 6,097.20 | 10.80 | 1,201 | 27.83 | 50.48 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
11.46 %
Net Income Growth
34.78 %
Cash Flow Change
27.97 %
ROE
14.34 %
ROCE
29.17 %
EBITDA Margin (Avg.)
18.76 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,821 | 2,238 | 2,607 | 3,554 | 3,994 |
| Fixed Assets | 329 | 440 | 679 | 640 | 621 | 651 | 634 | 1,277 | 1,901 | 2,004 |
| Current Assets | 901 | 816 | 795 | 1,047 | 1,051 | 1,073 | 1,553 | 1,253 | 1,528 | 1,853 |
| Capital Work in Progress | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 |
| Investments | 367 | 479 | 411 | 434 | 457 | 403 | 678 | 13 | 206 | 388 |
| Other Assets | 737 | 594 | 580 | 674 | 699 | 750 | 901 | 1,299 | 1,392 | 1,525 |
| Total Liabilities | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,821 | 2,238 | 2,607 | 3,554 | 3,994 |
| Current Liabilities | 460 | 431 | 281 | 275 | 244 | 313 | 345 | 384 | 554 | 868 |
| Non Current Liabilities | 33 | 31 | 27 | 46 | 65 | 69 | 79 | 85 | 519 | 203 |
| Total Equity | 995 | 1,186 | 1,366 | 1,444 | 1,483 | 1,438 | 1,813 | 2,139 | 2,480 | 2,923 |
| Reserve & Surplus | 978 | 1,167 | 1,347 | 1,425 | 1,464 | 1,420 | 1,794 | 2,119 | 2,465 | 2,908 |
| Share Capital | 17 | 17 | 17 | 17 | 16 | 16 | 16 | 16 | 16 | 16 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 13 | 15 | -28 | 43 | 11 | -6 | -3 | 34 | 20 | 11 |
| Investing Activities | -112 | -26 | -45 | -21 | -28 | 24 | -231 | 2 | -962 | -404 |
| Operating Activities | 127 | 140 | 201 | 123 | 194 | 276 | 315 | 170 | 626 | 801 |
| Financing Activities | -1 | -100 | -184 | -60 | -156 | -306 | -87 | -138 | 357 | -386 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 55.91 % | 55.91 % | 55.91 % | 54.00 % | 54.00 % | 54.00 % | 53.96 % | 53.95 % | 53.93 % | 53.91 % | 53.86 % | 53.83 % | 53.78 % | 53.77 % | 53.74 % | 53.66 % | 47.84 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.05 % | 0.00 % | 11.06 % | 12.17 % | 13.63 % | 14.64 % | 18.30 % |
| DIIs | 12.41 % | 12.32 % | 14.76 % | 16.03 % | 16.67 % | 17.52 % | 18.08 % | 18.54 % | 19.08 % | 18.65 % | 18.58 % | 17.97 % | 18.38 % | 17.62 % | 16.81 % | 16.41 % | 18.72 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % |
| Public / Retail | 20.50 % | 19.69 % | 17.64 % | 18.38 % | 17.87 % | 17.37 % | 16.94 % | 16.70 % | 15.98 % | 15.66 % | 15.34 % | 15.17 % | 14.69 % | 14.38 % | 13.87 % | 13.42 % | 13.28 % |
| Others | 11.18 % | 12.08 % | 11.70 % | 11.58 % | 11.47 % | 11.10 % | 11.02 % | 10.81 % | 11.00 % | 11.79 % | 2.17 % | 13.03 % | 2.09 % | 2.05 % | 1.94 % | 1.87 % | 1.86 % |
| No of Share Holders | 0 | 65,715 | 70,740 | 71,788 | 64,861 | 61,314 | 60,268 | 58,629 | 56,633 | 55,965 | 60,817 | 63,230 | 63,892 | 66,953 | 62,743 | 62,081 | 63,948 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 5 | 1 | 2 | 5 | 11 | 16.5 | 16.5 | 17.75 | 12.25 | 0.00 |
| Dividend Yield (%) | 2.89 | 0.64 | 1.1 | 1.96 | 1.75 | 2.1 | 1.67 | 1.08 | 0.75 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 14 May 2025 |  Quarterly Result Announcement | NA | 14 May 2025 | 1,658.70 | 1,579.85 |
| 08 Feb 2025 |  Dividend | ₹ 8.50 /share | 07 Feb 2025 | 1,714.10 | 1,673.75 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,805.05 | 1,714.10 |
| 06 Nov 2024 | Quarterly Result Announcement | NA | 06 Nov 2024 | 1,895.75 | 1,852.00 |
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 1,788.80 | 1,942.60 |
| 14 Aug 2024 | Dividend | ₹ 6.75 /share | 14 Aug 2024 | 1,832.55 | 1,941.60 |
| 16 Feb 2024 | Dividend | ₹ 5.50 /share | 16 Feb 2024 | 1,708.40 | 1,664.30 |
| 24 May 2023 |  Split | 1:2 | 18 Sept 2023 | 976.00 | 976.00 |
| 17 Aug 2023 | Dividend | ₹ 9.25 /share | 17 Aug 2023 | 976.00 | 1,315.08 |
| 18 Feb 2023 | Dividend | ₹ 8.50 /share | 17 Feb 2023 | 1,008.50 | 982.73 |
| 17 Aug 2022 | Dividend | ₹ 8.00 /share | 12 Aug 2022 | 785.18 | 931.68 |
| 24 Feb 2022 | Dividend | ₹ 8.50 /share | 23 Feb 2022 | 852.88 | 804.93 |
| 02 Sept 2021 | Dividend | ₹ 8.00 /share | 01 Sept 2021 | 770.03 | 850.15 |
| 22 Feb 2021 | Dividend | ₹ 8.50 /share | 18 Feb 2021 | 520.90 | 555.25 |
Announcements
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
May 15, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AMay 14, 2025
May 14, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 14, 2025
May 14, 2025Appointment Of Secretarial AuditorMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 14, 2025
May 14, 2025Corporate Action-Board approves DividendMay 14, 2025
May 14, 2025Audited Standalone & Consolidated Financial Results For The Year Ended On March 31 2025May 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
May 14, 2025Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Year Ended On March 31 2025 Accompanied By Auditors Report.May 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 23, 2025
Apr 23, 2025Board Meeting Intimation for (I) Consideration And Approval Of The Audited Financial Results For The Quarter And Year Ended On March 31 2025; And
(Ii) Consideration And Recommendation Of Dividend On Equity Shares Of The Company If Any Subject To ApprovaApr 22, 2025
Apr 22, 2025ANDA Approval By US FDAApr 18, 2025
Apr 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Apr 14, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 11, 2025
Apr 11, 2025Noting Of Cautionary Letter Received From The ExchangesApr 11, 2025
Apr 11, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Apr 01, 2025
Apr 01, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 29, 2025
Mar 29, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 18, 2025
Mar 18, 2025USFDA Inspection Of CompanyS API Manufacturing Facility - D9 At Panoli GujaratMar 14, 2025
Mar 14, 2025USFDA Inspection Of CompanyS Manufacturing Facility - T20 At Panoli GujaratMar 08, 2025
Mar 08, 2025DJSI (Dow Jones Sustainable Index) ESG Score ReleaseMar 05, 2025
Mar 05, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 27, 2025
Feb 27, 2025Intimation Of Schedule Of Analysts/Institutional Investors MeetFeb 19, 2025
Feb 19, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Feb 05, 2025Integrated Filing (Financial)Feb 04, 2025
Feb 04, 2025Board Comments On Fine Levied By The Exchange For Delayed ComplianceFeb 04, 2025
Feb 04, 2025Intimation Of Record DateFeb 04, 2025
Feb 04, 2025Corporate Action-Board approves DividendFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2025
Feb 04, 2025Unaudited Financial Results For The Quarter Ended On December 31 2024Feb 04, 2025
Feb 04, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Jan 24, 2025Board Meeting Intimation for (I) Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2024; And
(Ii) Consideration Of Declaration Of InterimJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 24, 2025
Jan 24, 2025PresentationJan 16, 2025
Jan 16, 2025Technical Indicators
RSI(14)
Neutral 59.03
ATR(14)
Less Volatile 45.92
STOCH(9,6)
Neutral 66.28
STOCH RSI(14)
Neutral 64.54
MACD(12,26)
Bullish 5.43
ADX(14)
Weak Trend 16.91
UO(9)
Bearish 55.14
ROC(12)
Uptrend But Slowing Down 4.82
WillR(14)
Neutral -20.51
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 WhiteOak Capital Special Opportunities Fund Direct - Growth | 70848 | 1.35% | -1.62% | 1.35% | Apr 2025 | |
| WhiteOak Capital Quality Equity Fund Direct-Growth | 21170 | 0.83% | 0.83% | 0.83% | Apr 2025 | |
 Axis Growth Opportunities Fund Direct-Growth | 0 | 0.00% | -0.39% | -0.41% | Apr 2025 | |
| WhiteOak Capital Multi Cap Fund Direct - Growth | 69406 | 0.65% | 0.31% | 0.43% | Apr 2025 | |
| Axis Multicap Fund Direct-Growth | 243390 | 0.54% | -0.31% | -0.41% | Apr 2025 | |
 Helios Mid Cap Fund Direct-Growth | 4461 | 0.97% | -0.30% | 0.97% | Apr 2025 | |
| WhiteOak Capital ELSS Tax Saver Fund Direct - Growth | 13402 | 0.60% | 0.23% | 0.44% | Apr 2025 | |
| WhiteOak Capital Flexi Cap Fund Direct - Growth | 162208 | 0.56% | 0.20% | 0.38% | Apr 2025 | |
 Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth | 0 | 0.00% | -0.17% | -0.17% | Apr 2025 | |
 Mirae Asset Small Cap Fund Direct-Growth | 128914 | 1.50% | -0.16% | -0.20% | Apr 2025 | |
 LIC MF Healthcare Fund Direct - Growth | 14752 | 2.83% | -0.16% | -0.44% | Apr 2025 | |
 Groww Multicap Fund Direct-Growth | 7364 | 1.29% | -0.15% | -0.41% | Apr 2025 | |
| WhiteOak Capital Equity Savings Fund Direct - Growth | 473 | 0.15% | 0.14% | 0.14% | Apr 2025 | |
 PGIM India Healthcare Fund Direct-Growth | 21014 | 3.15% | -0.12% | -0.43% | Apr 2025 | |
 Sundaram Long Term Tax Advantage Fund Series III Direct - Growth | 5362 | 2.78% | -0.11% | -0.28% | Apr 2025 | |
| PGIM India Retirement Fund Direct - Growth | 7940 | 1.59% | -0.11% | 0.00% | Apr 2025 | |
 Franklin India Smaller Companies Fund Direct-Growth | 1448723 | 1.86% | -0.10% | -0.25% | Apr 2025 | |
 Kotak MNC Fund Direct-Growth | 370000 | 2.77% | -0.10% | 0.34% | Apr 2025 | |
 Edelweiss Small Cap Fund Direct - Growth | 471131 | 1.79% | -0.09% | -0.29% | Apr 2025 | |
 Canara Robeco Multi Cap Fund Direct - Growth | 342649 | 1.37% | 0.09% | -0.03% | Apr 2025 | |
 Sundaram Long Term Tax Advantage Fund Series IV Direct - Growth | 2376 | 1.88% | -0.08% | -0.18% | Apr 2025 | |
| Canara Robeco Mid Cap Fund Direct - Growth | 236698 | 1.40% | -0.07% | 0.06% | Apr 2025 | |
| Canara Robeco Consumer Trends Fund Direct-Growth | 133000 | 1.20% | -0.07% | -0.18% | Apr 2025 | |
 Union Small Cap Fund Direct-Growth | 255996 | 2.81% | -0.07% | -0.27% | Apr 2025 | |
 Nippon India Pharma Fund Direct-Growth | 999649 | 1.95% | -0.06% | -0.20% | Apr 2025 |
About J B Chemicals and Pharmaceuticals
J.B. Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1976. It manufactures and markets a range of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. The company specializes in gastroenterology, hypertension, and dermatology, with additional focus on nephrology, respiratory, virology, diabetes, and nicotine replacement therapy. Key brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has manufacturing facilities in various locations in India and maintains a direct presence in Russia and South Africa, with distributor relationships in the US and other international markets. In 2020, Tau Investment Holdings Pte. Ltd., an affiliate of KKR, acquired a controlling stake in the company. J.B. Chemicals & Pharmaceuticals continues to expand its product portfolio through new launches and acquisitions in various therapeutic segments.
Website
Chairperson NameArun Duggal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
